Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study

Abstract

BackgroundCyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen includes a high dose of prednisolone (100 mg/body), which exhibits an anticancer and antiemetic effect. However, its optimal use for antiemetic therapy has not been established yet. We assessed the efficacy of granisetron plus aprepitant versus granisetron for CHOP or rituximab-CHOP (R-CHOP) regimen-induced nausea and vomiting in malignant lymphoma.MethodsThis retrospective and observational clinical study included patients who received CHOP or R-CHOP regimen as initiating chemotherapy between July 2010 and March 2016 (N = 39). Patients were assigned to an aprepitant [aprepitant (125 mg on day 1, 80 mg on days 2–3) plus granisetron (3 mg); n = 15] or control regimen group [granisetron (3 mg); n = 24]. Complete response (CR), defined as no vomiting and no use of rescue therapy during overall phase (0–120 h), was the primary endpoint. Secondary endpoints included the time to first vomiting and using rescue medication and complete protection (CP) defined as no vomiting and no retching and/or no nausea and no rescue therapy. The patient records were investigated, and data were retrospectively analyzed.ResultsCR rate CP rates did not significantly differ between the groups during the observation period (80.0% versus 83.3%, p = 1.000; and 80.0% versus 79.2%, p = 1.000, respectively). Additionally, the time to first vomiting and using rescue medication in did not significantly differ between the groups (p = 0.909).ConclusionsThis study suggests that granisetron alone could be one treatment option in the management of CINV in patients with non-Hodgkin lymphoma receiving CHOP or R-CHOP regimen.

Evaluation of Antiemetic Consistency in Chemotherapy-Induced Nausea and Vomiting Among NHL Patients in Sana’a, Yemen

“…12 Chemotherapy regimens received by patients with NHL were classified based on potential emetogenic risk into HEC, MEC, LEC, and minimal categories. 21,22 Patients receiving chemotherapy regimens that are categorized as MEC risk with additional risk factors such as being female, under the age of 50, and having a previous history of CINV, or those at the higher end of the risk spectrum, such as cyclophosphamide, carboplatin, doxorubicin, ifosfamide, and irinotecan, are at greater risk of emesis and require three antiemetic prophylactic medications. 12 Furthermore, NHL chemotherapy regimens were categorized as antiemetic therapy based on the drugs with the highest emetogenic risk in accordance with the guidelines, and the pattern of prescribing antiemetic regimens was evaluated based on the number of antiemetic prescriptions.…”